Developments in the immunophenotypic analysis of haematological malignancies

Blood Reviews

Volumn 27, Issue 4, 2013, Pages 193-207

  Heel, Kathy ^a   Tabone, Tania ^a   Röhrig, Kimberley J ^a   Maslen, Phillip G ^a   Meehan, Katie ^a   Grimwade, Lizz F ^b   Erber, Wendy N ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Bone marrow; Flow cytometry; Immunocytochemistry; Immunophenotyping

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CELL ANTIGEN; EPRATUZUMAB; FLUORESCENT DYE; INTERCELLULAR ADHESION MOLECULE 1; MONOCLONAL ANTIBODY; MYELOPEROXIDASE; RITUXIMAB; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTIBODY SPECIFICITY; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; AUTOMATION; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER PROGNOSIS; CANCER STAGING; CLASSICAL HODGKIN LYMPHOMA; CLINICAL DECISION MAKING; CLONAL VARIATION; COMPUTER PROGRAM; CYTOMETRY; DATA PROCESSING; DIGITAL IMAGING; DNA MICROARRAY; DRUG INDICATION; DRUG TARGETING; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENOTYPE PHENOTYPE CORRELATION; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HUMAN; IMAGING FLOW CYTOMETRY; IMMUNOCYTOCHEMISTRY; IMMUNOPHENOTYPING; INFORMATION STORAGE; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MASS CYTOMETRY; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS TECHNOLOGY; TISSUE MICROARRAY; WORLD HEALTH ORGANIZATION;

BONE MARROW; FLOW CYTOMETRY; IMMUNOCYTOCHEMISTRY; IMMUNOPHENOTYPING;

HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING;

EID: 84881373778     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.06.005     Document Type: Article

References (123)

1. Coons A.H., Creech H.J., Jones R. Immunological properties of an antibody containing a fluorescent group. Proc Soc Exp Med 1941, 47:2.
2. Craig F.E., Foon K.A. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008, 111:3941-3967.
3. Wood B. 9-color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 2006, 130(5):680-690.
4. Sternberger L.A., Hardy P.H., Cuculis J.J., Meyer H.G. The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 1970, 18(5):315-333.
5. Cordell J.L., Falini B., Erber W.N., Ghosh A.K., Abdulaziz Z., MacDonald S., et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984, 32(2):219-229.
6. Erber W.N., Mason D.Y. Immuno-alkaline phosphatase labelling of haematological samples: technique and applications. Leuk Res 1985, 9(6):829-830.
7. Erber W.N., Mynheer L.C., Mason D.Y. APAAP labelling of blood and bone-marrow samples for phenotyping leukaemia. Lancet 1986, 1(8484):761-765.
8. Fernandez V., Salamero O., Espinet B., Sole F., Royo C., Navarro A., et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010, 15(70):1408-1418.
9. Davis B.H., Holden J.T., Bene M.C., Borowitz M.J., Braylan R.C., Cornfield D., et al. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry B Clin Cytom 2007, 72(Suppl. 1):S5-S13.
10. Olsen R.J., Chang C.C., Herrick J.L., Zu Y., Ehsan A. Acute leukemia immunohistochemistry: a systematic diagnostic approach. Arch Pathol Lab Med 2008, 132(3):462-475.
11. Garcia C.F., Swerdlow S.H. Best practices in contemporary diagnostic immunohistochemistry: panel approach to hematolymphoid proliferations. Arch Pathol Lab Med 2009, 133(5):756-765.
12. van de Loosdrecht A.A., Alhan C., Béné M.C., Della Porta M.G., Dräger A.M., Feuillard J., et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009, 94(8):1124-1134.
13. Bain B.J., Barnett D., Linch D., Matutes E., Reilly J.T. General haematology task force of the British Committee for Standards in Haematology (BCSH). British society of haematology. Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. Clin Lab Haematol 2002, 24(1):1-13.
14. Béné M.C., Nebe T., Bettelheim P., Buldini B., Bumbea H., Kern W., et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia 2011, 25(4):567-574.
15. Kalina T., Flores-Montero J., van der Velden V.H., Martin-Ayuso M., Böttcher S., Ritgen M., et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols 2012, 26(9):1986-2010.
16. van Dongen J.J., Lhermitte L., Böttcher S., Almeida J., van der Velden V.H., Flores-Montero J., et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012, 26(9):1908-1975.
17. Porwit A. Immunophenotyping of selected hematologic disorders - focus on lymphoproliferative disorders with more than one malignant cell population. Int J Lab Hematol 2013, 35(3):275-282.
18. Basiji D.A., Ortyn W.E., Liang L., Venkatachalam V., Morrissey P. Cellular image analysis and imaging by flow cytometry. Clin Lab Med 2007, 27(3):653-670.
19. Grimwade L., Gudgin E., Bloxham D., Scott M.A., Erber W.N. PML protein analysis using imaging flow cytometry. J Clin Pathol 2011, 64(5):447-450.
20. Mirabelli P., Scalia G., Pascariello C., D'Alessio F., Mariotti E., Di Noto R., et al. ImageStream promyelocytic leukemia protein immunolocalization: in search of promyelocytic leukemia cells. Cytometry A 2012, 81(3):232-237.
21. Grimwade L., Gudgin E., Bloxham D., Bottley G., Vassiliou G., Huntly B., et al. Detection of cytoplasmic nucleophosmin expression by imaging flow cytometry. Cytometry A 2012, 81(10):896-900.
22. Bandura D.R., Baranov V.I., Ornatsky O.I., Antonov A., Kinach R., Lou X., et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal Chem 2009, 81(16):6813-6822.
23. Bendall S.C., Nolan G.P., Roederer M., Chattopadhyay P.K. A deep profiler's guide to cytometry. Trends Immunol 2012, 33:323-332.
24. Bodenmiller B., Zunder E.R., Finck R., Chen T.J., Savig E.S., Bruggner R.V., et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol 2012, 30(9):858-867.
25. Erber W.N. Immunocytochemistry. Diagnostic techniques in hematological malignancies 2010, 28-50. Cambridge University Press. W.N. Erber (Ed.).
26. Happerfield L.C., Saward R., Grimwade L., Bloxham D., Erber W.N. Automated immunostaining of cell smears: an alternative to flow cytometry. J Clin Pathol 2008, 61(6):740-743.
27. Packeisen J., Packeisen J., Korsching E., Herbst H., Boecker W., Buerger H., et al. Demystified tissue microarray technology. Mol Pathol 2003, 56(4):198-204.
28. Kononen J., Bubendorf L., Kallioniemi A., Bärlund M., Schraml P., Leighton S., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4(7):844-847.
29. Lahrmann B., Halama N., Westphal K., Ernst C., Elsawaf Z., Sinn P., et al. Robust gridding of TMAs after whole-slide imaging using template matching. Cytometry A 2010, 77(12):1169-1176.
30. Wang Y., Savage K., Grills C., McCavigan A., James J.A., Fennell D.A., et al. A TMA de-arraying method for high throughput biomarker discovery in tissue research. PLoS One 2011, 6(10):e26007.
31. Sauter G. Representativity of TMA studies. Methods Mol Biol 2010, 664:27-35.
32. Camp R.L., Neumeister V., Rimm D.L. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008, 26(34):5630-5637.
33. Franco R., Caraglia M., Facchini G., Abbruzzese A., Botti G. The role of tissue microarray in the era of target-based agents. Expert Rev Anticancer Ther 2011, 11(6):859-869.
34. Hewitt S.M. Tissue microarrays as a tool in the discovery and validation of predictive biomarkers. Methods Mol Biol 2012, 823:201-214.
35. Belov L., Mulligan S.P., Barber N., Woolfson A., Scott M., Stoner K., et al. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol 2006, 135(2):184-197.
36. Kohnke P.L., Mulligan S.P., Christopherson R.I. Membrane proteomics for leukemia classification and drug target identification. Curr Opin Mol Ther 2009, 11(6):603-610.
37. Erber W.N., McLachlan Use of APAAP technique on paraffin wax embedded bone marrow trephines. J Clin Pathol 1989, 42(11):1201-1205.
38. Erber W.N., Willis J.I., Hoffman G.J. An enhanced immunocytochemical method for staining bone marrow trephine sections. J Clin Pathol 1997, 50(5):389-393.
39. Stetler-Stevenson M., Yuan C.M. Flow cytometry. Diagnostic techniques in hematological malignancies 2010, 51-70. Cambridge University Press. W.N. Erber (Ed.).
40. Gaiser T., Bernhards J. Tyramide signal amplification: an enhanced method for immunohistochemistry on methyl-methacrylate-embedded bone marrow trephine sections. Acta Haematol 2007, 117(2):122-127.
41. Torlakovic E.E., Naresh K., Kremer M., van der Walt J., Hyjek E., Porwit A. Call for a European programme in external quality assurance for bone marrow immunohistochemistry; report of a European Bone Marrow Working Group pilot study. J Clin Pathol 2009, 62(6):547-551.
42. Costa E.S., Pedreira C.E., Barrena S., Lecrevisse Q., Flores J., Quijano S., et al. Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia 2010, 24(11):1927-1933.
43. Robinson J.P., Rajwa B., Patsekin V., Davisson V.J. Computational analysis of high-throughput flow cytometry data. Expert Opin Drug Discov 2012, 7(8):679-693.
44. Zare H., Bashashati A., Kridel R., Aghaeepour N., Haffari G., Connors J.M., et al. Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma. Am J Clin Pathol 2012, 137(1):75-85.
45. Cualing H.D., Zhong E., Moscinski L. "Virtual flow cytometry" of immunostained lymphocytes on microscopic tissue slides: iHCFlow tissue cytometry. Cytometry B Clin Cytom 2007, 72(1):63-76.
46. Dugas M., Schoch C., Schnittger S., Haferlach T., Danhauser-Riedl S., Hiddemann W., et al. A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping. Leukemia 2001, 15(12):1805-1810.
47. Dunphy C.H. Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology. Arch Pathol Lab Med 2004, 128(9):1004-1022.
48. Calvo K.R., McCoy C.S., Stetler-Stevenson M. Flow cytometry immunophenotyping of hematolymphoid neoplasia. Methods Mol Biol 2011, 699:295-316.
49. van Dongen J.J., Orfao A., EuroFlow Consortium EuroFlow: resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. Leukemia 2012, 26(9):1899-1907.
50. Gudgin E.J., Erber W.N. Immunophenotyping of lymphoproliferative disorders: state of the art. Pathology 2005, 37(6):457-478.
51. Paietta E., Goloubeva O., Neuberg D., Bennett J.M., Gallagher R., Racevskis J., et al. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry B Clin Cytometry 2004, 59(1):1-9.
52. Zhou Y., Jorgensen J.L., Wang S.A., Ravandi F., Cortes J., Kantarjian H.M., et al. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol 2012, 138:744-750.
53. Dong H.Y., Kung J.X., Bhardwaj V., McGill J. Flow cytometry rapidly identifies all acute promyelocytic leukemias with high specificity independent of underlying cytogenetic abnormalities. Am J Clin Pathol 2011, 135:76-84.
54. Dekking E.H., van der Velden V.H., Varro R., Wai H., Böttcher S., Kneba M., et al. Flow cytometric immunobead assay for fast and easy detection of PML-RARA fusion proteins for the diagnosis of acute promyelocytic leukemia. Leukemia 2012, 26(9):1976-1985.
55. Coustan-Smith E., Mullighan C.G., Onciu M., Behm F.G., Raimondi S.C., Pei D., et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009, 10:147-156.
56. Zhang J., Ding L., Holmfeldt L., Wu G., Heatley S.L., Payne-Turner D., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
57. Falini B., Tiacci E., Liso A., Basso K., Sabattini E., Pacini R., et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004, 363(9424):1869-1870.
58. Jöhrens K., Stein H., Anagnostopoulos I. T-bet transcription factor detection facilitates the diagnosis of minimal hairy cell leukemia infiltrates in bone marrow trephines. Am J Surg Pathol 2007, 31(8):1181-1185.
59. Sherman M.J., Hanson C.A., Hoyer J.D. An assessment of the usefulness of immunohistochemical stains in the diagnosis of hairy cell leukemia. Am J Clin Pathol 2011, 136(3):390-399.
60. Tiacci E., Trifonov V., Schiavoni G., Holmes A., Kern W., Martelli M.P., et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011, 364(24):2305-2315.
61. Tiacci E., Schiavoni G., Martelli M.P., Boveri E., Pacini R., Tabarrini A., et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica 2013, 98(4):635-639.
62. Andrulis M., Penzel R., Weichert W., von Deimling A., Capper D. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012, 36(12):1796-1800.
63. Todd T., Erber W.N. Diagnosis of leukaemic phase of angioimmunoblastic T-cell lymphoma from the peripheral blood. Br J Haematol 2006, 134(2):124.
64. Baseggio L., Berger F., Morel D., Delfau-Larue M.H., Goedert G., Salles G., et al. Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma. Leukemia 2006, 20(2):296-303.
65. Baseggio L., Traverse-Glehen A., Berger F., Ffrench M., Jallades L., Morel D., et al. CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma. Mod Pathol 2011, 24(7):993-1003.
66. Nakayama-Ichiyama S., Yokote T., Hirata Y., Iwaki K., Akioka T., Miyoshi T., et al. Immunohistological diagnosis of plasma cell myeloma based on cytoplasmic kappa/lambda ratio of CD138-positive plasma cells. Leuk Lymphoma 2012, 53:2205-2209.
67. Morice W.G. The immunophenotypic attributes of NK cells and NK-cell lineage lymphoproliferative disorders. Am J Clin Pathol 2007, 127(6):881-886.
68. Pulitzer M., Brady M.S., Blochin E., Amin B., Teruya-Feldstein J. Anaplastic large cell lymphoma: a potential pitfall in the differential diagnosis of melanoma. Arch Pathol Lab Med 2013, 137(2):280-283.
69. Rodríguez-Vicente A.E., Díaz M.G., Hernández-Rivas J.M. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer Genet 2013, 206(3):49-62.
70. Rosenquist R., Cortese D., Bhoi S., Mansouri L., Gunnarsson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?. Leuk Lymphoma Apr 30 2013, [Epub ahead of print]. 10.3109/10428194.2013.783913.
71. Röhrs S., Scherr M., Romani J., Zaborski M., Drexler H.G., Quentmeier H. CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation. J Hematol Oncol 2010, 3:15.
72. Plesa C., Chelghoum Y., Plesa A., Elhamri M., Tigaud I., Michallet M., et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer 2008, 112(3):572-580.
73. Dang H., Jiang A., Kamel-Reid S., Brandwein J., Chang H. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype. Hum Pathol 2013, 44(1):55-61.
74. Metzeler K.H., Heilmeier B., Edmaier K.E., Rawat V.P., Dufour A., Döhner K., et al. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood 2012, 120(1):2118-2126.
75. Lee S.T., Jang J.H., Min Y.H., Hahn J.S., Ko Y.W. AC133 antigen as a prognostic factor in acute leukemia. Leuk Res 2001, 25(9):757-767.
76. Wuchter C., Ratei R., Spahn G., Schoch C., Harbott J., Schnittger S., et al. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica 2001, 86(2):154-161.
77. Tolba F.M., Foda M.E., Kamal H.M., Elshabrawy D.A. Expression of CD133 in acute leukemia. Med Oncol 2013, 30(2):527.
78. Mozos A., Royo C., Hartmann E., De Jong D., Baró C., Valera A., et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009, 94(11):1555-1562.
79. Navarro A., Clot G., Royo C., Jares P., Hadzidimitriou A., Agathangelidis A., et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012, 72(20):5307-5316.
80. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103(1):275-282.
81. Choi W.W., Weisenburger D.D., Greiner T.C., Piris M.A., Banham A.H., Delabie J., et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009, 15(17):5494-5502.
82. de Jong D., Xie W., Rosenwald A., Chhanabhai M., Gaulard P., Klapper W., et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Pathol 2009, 62(2):128-138.
83. Salles G., de Jong D., Xie W., Rosenwald A., Chhanabhai M., Gaulard P., et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011, 117(26):7070-7078.
84. Bisig B., Gaulard P., de Leval L. New biomarkers in T-cell lymphomas. Best Pract Res Clin Haematol 2012, 25(1):13-28.
85. Zhang Q.Y., Foucar K. Bone marrow involvement by Hodgkin and non-Hodgkin lymphomas. Hematol Oncol Clin North Am 2009, 23(4):873-902.
86. Dogan A., Herrick J. Lymphoma. Diagnostic techniques in hematological malignancies 2010, 206-243. Cambridge University Press. W.N. Erber (Ed.).
87. Fraga M., Brousset P., Schlaifer D., Payen C., Robert A., Rubie H., et al. Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 1995, 103(1):82-89.
88. Gudgin E., Rashbass J., Pulford K.J., Erber W.N. Primary and isolated anaplastic large cell lymphoma of the bone marrow. Leuk Lymphoma 2005, 46(3):461-463.
89. Rawstron A.C., Bennett F.L., O'Connor S.J., Kwok M., Fenton J.A., Plummer M., et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008, 359(6):575-583.
90. Rawstron A.C., Hillmen P. Clinical and diagnostic implications of monoclonal B-cell lymphocytosis. Best Pract Res Clin Haematol 2010, 23(1):61-69.
91. Rawstron A.C. Monoclonal B, cell lymphocytosis-what does it really mean?. Curr Hematol Malig Rep 2013, 8(1):52-59.
92. Falini B., Martelli M.P., Bolli N., Bonasso R., Ghia E., Pallotta M.T., et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006, 108(6):1999-2005.
93. Falini B., Nicoletti I., Martelli M.F., Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+AML): biologic and clinical features. Blood 2007, 109(3):874-885.
94. Falini B., Martelli M.P., Bolli N., Sportoletti P., Liso A., Tiacci E., et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. Blood 2011, 117(4):1109-1120.
95. Cook J.R., Hartke M., Pettay J., Tubbs R.R. Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence. J Mol Diagn 2006, 8(4):459-465.
96. Mattsson G., Tan S.Y., Ferguson D.J., Erber W., Turner S.H., Marafioti T., et al. Detection of genetic alterations by immunoFISH analysis of whole cells extracted from routine biopsy material. J Mol Diagn 2007, 9(4):479-489.
97. Fend F., Tzankov A., Bink K., Seidl S., Quintanilla-Martinez L., Kremer M., et al. Modern techniques for the diagnostic evaluation of the trephine bone marrow biopsy: methodological aspects and applications. Prog Histochem Cytochem 2008, 42(4):203-252.
98. Ansell S.M., Horwitz S.M., Engert A., Khan K.D., Lin T., Strair R., et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. JCO 2007, 25(19):2764-2769.
99. Waldmann T.A. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007, 26(25):3699-3703.
100. McEarchern J.A., Smith L.M., McDonagh C.F., Klussman K., Gordon K.A., Morris-Tilden C.A., et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 2008, 14:7763-7772.
101. Vinjamaram S., Czuczman M.S., Hernandez-Ilizaliturri F.J. The use of galiximab in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2008, 8(5):277-282.
102. Khubchandani S., Czuczman M.S., Hernandez-Ilizaliturri F.J. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr Opin Investig Drugs 2009, 10(6):579-587.
103. Law C.L., McEarchern J.A., Grewal I.S. Novel antibody-based therapeutic agents targeting CD70: a potential approach for treating Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009, 9(1):90-93.
104. Lee M., Advani R. Targeting CD40 in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma 2009, 9(1):87-89.
105. Hoelzer D. Novel antibody-based therapies for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2011, 243-249.
106. Micallef I.N., Maurer M.J., Wiseman G.A., Ni110kcevich D.A., Kurtin P.J., Cannon M.W., et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 2011, 118(15):4053-4061.
107. Younes A. CD30-targeted antibody therapy. Curr Opin Oncol 2011, 23(6):587-593.
108. Czuczman M.S., Leonard J.P., Jung S., Johnson J.L., Hsi E.D., Byrd J.C., et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol 2012, 23(9):2356-2362.
109. Hoelzer D., Gokbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012, 26(1):25-32.
110. Matutes E. Novel and emerging drugs for rarer chronic lymphoid leukaemias. Curr Cancer Drug Targets 2012, 12(5):484-504.
111. Pettitt A.R., Jackson R., Carruthers S., Dodd J., Dodd S., Oates M., et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. JCO 2012, 30(14):1647-1655.
112. Kreitman R.J. CD138 or cytoplasmic immunoglobulin. Hematology Am Soc Hematol Educ Program 2012, 2012:660-666.
113. Portell C.A., Advani A.S. Antibody therapy for acute lymphoblastic leukemia. Curr Hematol Malig Rep 2012, 7(2):153-159.
114. Sharkey R.M., Govindan S.V., Cardillo T.M., Goldenberg D.M. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. Mol Cancer Ther 2012, 11(1):224-234.
115. Rousseau C., Ferrer L., Supiot S., Bardiès M., Davodeau F., Faivre-Chauvet A., et al. Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients. Tumour Biol 2012, 33(3):679-688.
116. Wasik M.A., Jimenez G.S., Weisenburger D.D. Targeting CD30 in malignant tissues: challenges in detection and clinical applications. Pathobiology 2013, 80:252-258.
117. Smith S.M., Schöder H., Johnson J.L., Jung S.H., Bartlett N.L., Cheson B.D. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma 2013 Jan 3, [ePub]. 10.3109/10428194.2012.744453.
118. Hedley B.D., Keeney M. Technical issues: flow cytometry and rare event analysis. Int J Lab Hematol 2013, 35:344-350.
119. Roshal M., Fromm J.R., Winter S., Dunsmore K., Wood B.L. Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection. Cytometry B Clin Cytom 2010, 78(3):139-146.
120. Loken M.R., Alonzo T.A., Pardo L., Gerbing R.B., Raimondi S.C., Hirsch B.A., et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012, 120(8):1581-1588.
121. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol 2009, 46(1):100-106.
122. Schuurhuis G.J., Ossenkoppele G. Minimal residual disease in acute myeloid leukemia: already predicting a safe haven?. Expert Rev Hematol 2010, 3(1):1-5.
123. Westers T.M., Ireland R., Kern W., Alhan C., Balleisen J.S., Bettelheim P., et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012, 26(7):1730-1741.